Abstract 1685P
Background
Family caregivers play a vital role in cancer care, yet their effective integration, needs assessment, and support in German outpatient settings require further examination. This qualitative study explores family caregivers' experiences, preferences, and integration challenges, employing a unique dyadic approach to analyze patient-caregiver dynamics and incorporating oncologists' perspectives on effective caregiver integration. It also suggests areas of potential integration of innovative technologies to address these challenges.
Methods
The study uses a reflexive thematic analysis of qualitative semi-structured interviews with 15 patient-caregiver dyads involving advanced cancer patients with solid tumours and three oncologists at a German outpatient cancer centre.
Results
Three interconnected themes emerged: 1) The multifaceted impact of illness on patient-caregiver dyads, emphasizing the significance of dyadic support and incongruence; 2) Communication with physicians and understanding of healthcare Information, stressing the need for tailored prognostic communication, and considering health literacy aspects; 3) Navigating healthcare services and psychosocial support, underlining the importance of a regular needs and distress evaluation, providing personalized support in the form of a referral and proactive guidance upon cancer diagnosis.
Conclusions
The study's findings have practical implications for healthcare practice and policy. Healthcare systems should adopt a more caregiver-inclusive approach that provides proactive psychosocial support at the beginning of the cancer journey, and tailored communication with healthcare professionals. This approach could include developing and implementing targeted digital tools that allow automated needs evaluation and incorporation of referrals for specialized support programs for cancer caregivers. The future investigation and implementation of such innovative technologies is important, as they have the potential to reduce the caregiving burden and significantly enhance the overall quality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Rose: Other, Institutional, Leadership Role: Head of Promis National Center Germany. All other authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11